NCT06527781View on ClinicalTrials.gov

A Study of PD5K3 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions
Lymphoblastic Leukemia, AcuteLymphoblastic Lymphoma
Interventions
DRUG

PD5K3

Six dose levels will be evaluated. intravenous injection

DRUG

Placebo

intravenous injection

DRUG

Pegaspargase

Six dose levels will be evaluated. intramuscular injection

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Chongqing Peg-Bio Biopharm Co., Ltd.

INDUSTRY

NCT06527781 - A Study of PD5K3 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter